A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Latest Information Update: 10 Oct 2024
At a glance
- Drugs Acalabrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms MAJIC
- Sponsors AstraZeneca; AstraZeneca AB
- 15 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Jan 2024 Planned number of patients changed from 600 to 602.
- 12 Jan 2024 Planned primary completion date changed from 3 May 2027 to 15 Jul 2027.